CY1110252T1 - Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ - Google Patents

Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ

Info

Publication number
CY1110252T1
CY1110252T1 CY20081100519T CY081100519T CY1110252T1 CY 1110252 T1 CY1110252 T1 CY 1110252T1 CY 20081100519 T CY20081100519 T CY 20081100519T CY 081100519 T CY081100519 T CY 081100519T CY 1110252 T1 CY1110252 T1 CY 1110252T1
Authority
CY
Cyprus
Prior art keywords
diagnosis
disease
alzheimer
altzaimer
prevalence
Prior art date
Application number
CY20081100519T
Other languages
English (en)
Inventor
Hugo Vanderstichele
Eugeen Vanmechelen
Kaj Blennow
Meyer Geert De
Vesna Kostanjevecki
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of CY1110252T1 publication Critical patent/CY1110252T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medical Treatment And Welfare Office Work (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Δίδονται μέθοδοι για την προβλέψη, διάγνωση και διαφορική διάγνωση της νόσου του Αλτζχάιμερ. Πιο συγκεκριμένα, δίδεται μία μέθοδος για να προσδιοριστεί εάν ένα άτομο που δεν παρουσιάζει κάποιες κλινικές ενδείξεις νόσου του Αλτζχάιμερ έχει μία πιθανότητα ν’ αναπτύξει νόσο του Αλτζχάιμερ. Περαιτέρω δίδεται μία μέθοδος για τη διάγνωση ατόμων που πάσχουν από νόσο του Αλτζχάιμερ και/ή για τη διαφορική διάγνωση ατόμων που πασχουν από τη νόσο του Αλτζχάιμερ έναντι ατόμων που πάσχουν από άλλες άνοιες όπως άνοια με σωμάτια Lewy. Οι μέθοδοι βασίζονται στον προσδιορισμό της αναλογίας των εξειδικευμένων Αβ πεπτιδίων.
CY20081100519T 2003-05-22 2008-05-20 Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ CY1110252T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03447120A EP1480041A1 (en) 2003-05-22 2003-05-22 Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease
US47762103P 2003-06-11 2003-06-11
EP04730881A EP1625403B1 (en) 2003-05-22 2004-05-03 Method for the prediction, diagnosis and differential diagnosis of alzheimer s disease

Publications (1)

Publication Number Publication Date
CY1110252T1 true CY1110252T1 (el) 2015-01-14

Family

ID=33041166

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100519T CY1110252T1 (el) 2003-05-22 2008-05-20 Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ

Country Status (14)

Country Link
US (2) US20040265919A1 (el)
EP (2) EP1480041A1 (el)
JP (1) JP4769722B2 (el)
AT (1) ATE386942T1 (el)
AU (1) AU2004242203B2 (el)
CA (1) CA2525781C (el)
CY (1) CY1110252T1 (el)
DE (1) DE602004011931T2 (el)
DK (1) DK1625403T3 (el)
ES (1) ES2301986T3 (el)
PL (1) PL1625403T3 (el)
PT (1) PT1625403E (el)
SI (1) SI1625403T1 (el)
WO (1) WO2004104597A1 (el)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7179892B2 (en) * 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PE20050627A1 (es) 2003-05-30 2005-08-10 Wyeth Corp Anticuerpos humanizados que reconocen el peptido beta amiloideo
EP1771715A4 (en) * 2004-07-19 2009-04-22 Mayo Foundation PREDICTION OF ALZHEIMER DISEASE
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
KR20080090408A (ko) 2005-11-30 2008-10-08 아보트 러보러터리즈 항-Ａβ 글로불로머 항체, 이의 항원-결합 잔기, 상응하는하이브리도마, 핵산, 벡터, 숙주 세포, 당해 항체의 제조방법, 당해 항체를 포함하는 조성물, 당해 항체의 용도 및당해 항체의 사용 방법
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
RU2551782C2 (ru) 2005-12-12 2015-05-27 Ац Иммуне Са Специфические в отношении амилоида бета (а бета) 1-42 моноклональные антитела, обладающие терапевтическими свойствами
JP4790013B2 (ja) * 2006-04-13 2011-10-12 エーディア株式会社 β−アミロイドの血中分解速度測定によるアルツハイマー病の検定に用いられる方法及び診断試薬
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
WO2009017467A1 (en) 2007-07-27 2009-02-05 Elan Pharma International Limited Treatment of amyloidogenic diseases
PL2046833T3 (pl) 2006-07-14 2014-01-31 Ac Immune Sa Humanizowane przeciwciało przeciw amyloidowi beta
CA2669848A1 (en) * 2006-11-17 2008-05-22 Friedrich-Alexander-Universitaet Erlangen-Nuernberg Method of differentially diagnosing dementias
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
JP5607543B2 (ja) * 2008-02-01 2014-10-15 ベー．エル．アー．ハー．エム．エス ゲゼルシャフト ミット ベシュレンクテル ハフツング 治療に必要な軽度認知障害患者の特定方法とかかる患者の治療剤
JP5828762B2 (ja) * 2008-07-21 2015-12-09 プロビオドルグ エージー 診断用抗体アッセイ
AU2009295357A1 (en) * 2008-09-26 2010-04-01 The University Of Melbourne Alzheimer's disease biomarkers
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SG10201405802UA (en) * 2009-09-18 2014-11-27 Probiodrug Ag Novel assay for the detection of amyloid beta peptides
DK2510359T3 (en) * 2009-12-11 2015-12-07 Araclón Biotech S L METHODS AND REAGENTS FOR IMPROVED DETECTION OF AMYLOID-BETA PEPTIDES
DE102010014684A1 (de) * 2010-04-09 2011-10-13 Universität Duisburg-Essen Neue Ansätze zur Alzheimer-Diagnose
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
JP6081356B2 (ja) 2010-07-30 2017-02-15 エーシー イミューン エス．エー． 安全で機能的なヒト化抗βアミロイド抗体
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
EP2511296A1 (en) 2011-04-12 2012-10-17 Araclón Biotech, S. L. Antibody, kit and method for determination of amyloid peptides
JP6231263B2 (ja) * 2012-07-17 2017-11-15 株式会社島津製作所 アフィニティ支持体及びそれを用いた物質の捕捉方法
BR112015003326A2 (pt) 2012-08-16 2017-07-04 Ipierian Inc métodos de tratamento de uma tauopatia
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
US10304006B2 (en) * 2013-02-15 2019-05-28 The Charles Stark Draper Laboratory, Inc. Method for integrating and fusing heterogeneous data types to perform predictive analysis
US10400018B2 (en) 2014-02-14 2019-09-03 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
US20180252665A1 (en) * 2014-05-27 2018-09-06 Case Western Reserve University System and methods for the detection of biomarkers of neurodegenerative disorders
EP2950102A1 (en) * 2014-05-30 2015-12-02 Biocross, S.L. Method for the diagnosis of alzheimer s disease and mild cognitive impairment
US20170242040A1 (en) * 2014-05-30 2017-08-24 Biocross, S.L. Method for the diagnosis of alzheimer's disease and mild cognitive impairment
CN113884683A (zh) * 2020-07-30 2022-01-04 山东京济生物工程有限公司 一种快速检测Aβ42的双抗体夹心ELISA试剂盒
US20220260559A1 (en) * 2020-11-04 2022-08-18 Seer, Inc. Biomarkers for diagnosing alzheimer's disease
JP2024514049A (ja) * 2021-03-16 2024-03-28 ニューロビジョン イメージング， インコーポレイテッド アルツハイマー病関連状態を診断するための生物流体ベースの方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262332A (en) * 1989-04-05 1993-11-16 Brigham And Women's Hospital Diagnostic method for Alzheimer's disease: examination of non-neural tissue
US5766846A (en) * 1992-07-10 1998-06-16 Athena Neurosciences Methods of screening for compounds which inhibit soluble β-amyloid peptide production
ATE239797T1 (de) * 1993-01-25 2003-05-15 Takeda Chemical Industries Ltd Antikörper gegen beta-amyloid oder derivative davon und seine verwendung
EP1023464B1 (en) * 1997-10-14 2017-07-26 Luminex Corporation Precision fluorescently dyed particles and methods of making and using same
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20020182660A1 (en) * 2000-02-18 2002-12-05 Fong Kei-Lai L. N- and C-terminus specific immunoassays for full length beta-amyloid peptide-Abeta(1-40), Abeta(1-39), Abeta(1-40), Abeta(1-42) , and Abeta(1-43)
TWI255272B (en) * 2000-12-06 2006-05-21 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ATE277952T1 (de) * 2001-06-12 2004-10-15 Wiltfang Jens Monoklonaler antikörper, mbab 1e8, welcher für die zwei ersten n-terminalen aminosäuren von amyloid-beta-peptiden spezifisch ist und dessen verwendung zum nachweis von amyloid-beta peptiden und/oder sappa
ATE381346T1 (de) * 2001-08-17 2008-01-15 Univ Washington Assayverfahren für alzheimer-krankheit

Also Published As

Publication number Publication date
CA2525781A1 (en) 2004-12-02
PL1625403T3 (pl) 2008-10-31
WO2004104597A1 (en) 2004-12-02
EP1625403A1 (en) 2006-02-15
CA2525781C (en) 2013-08-13
DE602004011931T2 (de) 2009-09-10
JP4769722B2 (ja) 2011-09-07
AU2004242203A1 (en) 2004-12-02
DE602004011931D1 (de) 2008-04-03
JP2007522434A (ja) 2007-08-09
AU2004242203B2 (en) 2008-12-11
SI1625403T1 (sl) 2008-08-31
DK1625403T3 (da) 2008-06-09
ATE386942T1 (de) 2008-03-15
PT1625403E (pt) 2008-05-28
EP1625403B1 (en) 2008-02-20
EP1480041A1 (en) 2004-11-24
US20040265919A1 (en) 2004-12-30
ES2301986T3 (es) 2008-07-01
US20080057593A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
CY1110252T1 (el) Μεθοδος για την προβλεψη, διαγνωση και διαφορικη διαγνωση της νοσου του αλτζχαιμερ
ATE409047T1 (de) Humanisierte antikörper
ATE283485T1 (de) Verfahren zur diagnose und zur charakterisierung von schlaganfall
WO2005047484A3 (en) Biomarkers for alzheimer's disease
DE60331941D1 (de) Mutationen in nod2 sind bei patienten mit morbus crohn mit fibrostenosebildung assoziiert
DE69628758D1 (de) Identifikation von mutationen, die mit menschlicher alpha-thalassämie assoziiert sind, und ihre verwendung für die vorhersage von blutkrankheiten.
IL182540A0 (en) Method of assaying alzheimer's disease and diagnostic reagent
CY1110116T1 (el) Νευροεκφυλιστικοι δεικτες για καταθλιψη
DE60142693D1 (de) Arzneimittel für herzversagen
GB0100119D0 (en) Materials and methods relating to protein aggregation in neurodegenerative disease
DE60322848D1 (de) System für kontinuierliche leistungstests
ATE551357T1 (de) Markerpeptid für die alzheimer-krankheit
WO2006067792A3 (en) Aldolase autoantigens useful in diagnosis and treatment of alzheimer's disease
WO2004041077A3 (en) Method for assessing navigational capacity
AU2002238766A1 (en) Diagnostic screens for alzheimer's disease
IL172690A0 (en) Methods for the diagnosis and prognosis of alzheimer's disease
WO2003036261A3 (en) Drug development by rapid neuroimaging of neural cells
AU2002366555A1 (en) Diagnostic for early stage alzheimer's disease
WO2006032021A3 (en) Identification of gene associated with reading disability and uses therefor
AU2003236714A8 (en) Diagnosis of alzheimer's disease based on the habeta42:habeta40 ratio
DE60127901D1 (de) TCF-1 Nukleotidsequenzvariation
EP1693671A4 (en) METHOD FOR DIAGNOSING ALZHEIMER'S DISEASE
ATE481498T1 (de) Verfahren zur messung von neprilysinaktivität
WO2004081576A3 (en) Association of polymorphic kinase anchor proteins with cardiac phenotypes and related methods
WO2005059562A3 (en) Diagnostic and therapeutic use of the human hif3alpha gene and proteins for neurodegenerative diseases